Business Context and Reporting Period
This Form 8-K filing by 22nd Century Group, Inc. (NASDAQ: XXII) reports a corporate governance event dated September 7, 2022, with the report filed on September 12, 2022. The filing details the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors expanded from seven to eight members.
- New Appointment: Lucille S. Salhany was appointed as a Class III director, effective immediately.
- Independence: Ms. Salhany is deemed independent under NASDAQ rules.
Guidance, Outlook, and Management Commentary
Management Commentary: The appointment of Ms. Salhany was made pursuant to the terms of the Reorganization and Acquisition Agreement with GVB Biopharma ("GVB"). She was nominated by the Governance and Nominating Committee. The Board intends to appoint her to specific Board committees at a future date.
Compensation: Ms. Salhany will receive the same compensation as the Company's other non-employee directors.
Risks and Contingencies: The filing states there are no reportable related party transactions involving Ms. Salhany or her immediate family. No other risks or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the terms of the Reorganization and Acquisition Agreement with GVB Biopharma to understand the strategic context of the appointment.
- Confirm the specific Board committees to which Ms. Salhany will be assigned once announced.
- Review the attached press release (Exhibit 99.1) for additional details on the director's background and the company's strategic direction.
- Check subsequent filings for the Company's financial status, as this 8-K contains no financial metrics.